Neuronetics
Medical technology company developing transcranial magnetic stimulation (TMS) devices
Last updated August 26, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Neuronetics is a medical technology company focused on developing transcranial magnetic stimulation (TMS) devices for treating major depressive disorder and other psychiatric conditions. Its flagship product, NeuroStar Advanced Therapy, is FDA-approved and used globally. Founded in 2003, headquartered in Malvern, Pennsylvania, and listed on NASDAQ.
Products and positioning
professional, clinically validated, innovative
Product categories. NeuroStar Advanced Therapy · TMS 设备
Recent events
Neuronetics prices $75 million public stock offering[1]
Neuronetics announced that it priced an underwritten public offering of 4,840,000 common shares at $15.50 per share. Gross proceeds are expected to be approximately $75 million before offering expenses; closing was expected on or about February 2, subject to customary conditions.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/neuronetics · Editorial policy · How profiles are compiled